## **LUPIN LIMITED**



Registered Office: Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai 400 055. Corporate Identity Number: L24100MH1983PLC029442

Tel: (91-22) 6640 2323

E-mail: info@lupin.com

Website: www.lupin.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

	Particulars	3 Months Ended 30/06/2023 (Unaudited)	3 Months Ended 31/03/2023 (Audited) (Refer note 5)	3 Months Ended 30/06/2022 (Unaudited)	(₹ in million Accounting Year Ended 31/03/202: (Audited
	Revenue from operations		07.445.0	00.044.0	440 400 =
	a) Sales / income from operations (Refer note 3)	34,250.1	27,445.6	26,841.9	110,430.7
	b) Other operating income	706.3	917.1	483.0	2,157.6
	Total Revenue from operations	34,956.4	28,362.7	27,324.9	112,588.3
2)	Other income	277.4	553.0	64.8	912.6
3)	Total income (1+2)	35,233.8	28,915.7	27,389.7	113,500.9
)	Expenses				
	a) Cost of materials consumed	8,296.4	7,885.8	6,961.2	31,512.0
	b) Purchases of stock-in-trade	4,555.4	3,238.5	4,345.4	15,257.0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade [(increase)/decrease]	(388.3)	819.1	428.2	1,207.9
	d) Employee benefits expense	5,237.9	4,621.3	5,049.5	19,341.4
	e) Finance cost	161.8	294.4	198.7	984.4
	,	1,400.5	1,462.0	1,303.5	5,483.4
	f) Depreciation, amortisation and impairment expense			8,441.9	
	g) Other expenses	10,121.6	8,972.8		35,631.0
	h) Net (gain) / loss on foreign currency transactions  Total expenses	83.2 29,468.5	203.4 27,497.3	(788.3) <b>25,940.1</b>	(1,187.6 108,229.5
	Profit / (Loss) before tax (3-4)	5,765.3	1,418.4	1,449.6	5,271.4
i)	Tax expense Current tax (net)	1,007.2	254.2	289.4	958.9
	Deferred tax (net)	(11.5)	(25.9)	(11.6)	60.4
	Total tax expense	995.7	228.3	277.8	1,019.3
')	Net Profit / (Loss) after tax (5-6)	4,769.6	1,190.1	1,171.8	4,252.1
	Other comprehensive income / (loss)				
	(a) (i) Items that will not be reclassified subsequently to profit or loss	(69.9)	(113.4)	199.8	(21.4
	<ul> <li>(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss</li> </ul>	24.4	39.6	(69.8)	7.5
	(b) (i) Items that will be reclassified subsequently to profit or loss	64.9	162.6	(251.8)	(295.5
	(ii) Income tax relating to items that will be reclassified to profit or loss	(14.5)	(37.1)	60.6	70.2
	Total other comprehensive income / (loss)	4.9	51.7	(61.2)	(239.2
9)	Total comprehensive income / (loss), net of tax (7+8)	4,774.5	1,241.8	1,110.6	4,012.9
0)	Paid up equity share capital (Face value ₹ 2/- each)	910.2	910.0	909.3	910.0
1)	Other equity				183,208.6
	Earnings per share (of ₹ 2/- each) (Not annualised for the quarters) a) Basic (in ₹) b) Diluted (in ₹)  a accompanying notes to the standalone (in €)  Barrings per share (of ₹ 2/- each) Central 8 Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway.	10.48 10.44	2.62 2.59	2.58 2.57	9.3 <del>4</del> 9.3
	House and the second				

## NOTES:

- The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of
  Directors at their meeting held on August 03, 2023. The Statutory Auditors of the Company have carried out limited review of the above
  Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
- 2. During the quarter, 98,683 equity shares of ₹ 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by ₹ 0.2 million and securities premium account by ₹ 91.6 million.
- 3. During the current quarter, Sales / Income from operations includes milestone income of ₹ 2,052.5 million (USD 25.0 million) from AbbVie for successful achievement of key milestone for its Phase 1 clinical stage MALT1 inhibitor program.
- 4. The Company operates in one reportable business segment i.e. "Pharmaceuticals".
- 5. The figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full previous financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2022. The year-to-date figures up to the third quarter ended December 31, 2022 were only subject to Limited Review and not audited.

INDIA MUMBAI M

By Order of the Board For Lupin Limited

Nilesh D. Gupta Managing Director DIN: 01734642

Place : Mumbai

Date : August 03, 2023

